Tempus AI's Q3 Performance Overview
AI company Tempus AI (NASDAQ:TEM) has recently unveiled strong financial results for the third quarter. This announcement, made after the market closed, has certainly caught the attention of investors and analysts alike.
Key Highlights of Q3
In the reported quarter, Tempus AI achieved impressive revenue figures of $334.21 million, representing a remarkable 84.7% increase year-over-year. This clearly outpaced the Street consensus estimate, which projected revenues around $328.73 million.
Genomics and Services Revenue
The revenue from Genomics alone reached $252.9 million, marking a staggering growth of 117.2% compared to the same period last year. Meanwhile, the revenue derived from data and services saw a healthy increase of 26.1%, bringing in $81.3 million.
Adjusted Loss and Earnings Performance
Tempus AI revealed an adjusted loss of 11 cents per share, which beat expectations where analysts had predicted a loss of 17 cents per share. This demonstrates improved operational efficiency amid rapid growth.
Innovations in Clinical Testing
The company noted it delivered around 217,000 clinical tests during the third quarter, which translates to a significant 33% growth from the previous year. This increase is indicative of the rising demand for oncology services, alongside a 27% uptick in oncology volume.
Growth in Financial Metrics
The gross profit for Tempus AI reached $209.9 million in the third quarter, marking an impressive 98.4% increase from the previous year. Furthermore, adjusted EBITDA showed substantial improvement, reaching $1.5 million compared to a loss of $21.8 million in the same quarter last year.
CEO's Insight on Journey Forward
CEO Eric Lefkofsky expressed pride in the company’s growth trajectory, highlighting that reaching positive adjusted EBITDA is a significant milestone that underscores the strength of their business model.
Future Outlook
As the company looks ahead, Tempus AI has revised its full-year revenue guidance for 2025, raising it to $1.265 billion from a prior estimate of $1.260 billion. This figure represents an anticipated year-over-year growth of about 80%.
Impact of Recent Acquisitions
Tempus AI's recent acquisition of Paige is projected to influence financials, with anticipated losses of around $5 million per quarter following the deal. The guidance indicates that the company expects fourth-quarter adjusted EBITDA to be approximately $20 million.
Market Response and Stock Performance
Following the announcement, Tempus AI’s stock experienced a decline of 12.13%, trading at $74.24 during after-hours sessions, which is notable given its 52-week trading range has shifted from $31.36 to $104.32.
Frequently Asked Questions
What financial results did Tempus AI report for Q3?
Tempus AI reported a revenue of $334.21 million for Q3, showcasing an 84.7% year-over-year growth.
How has Tempus AI performed in the genomics market?
The company reported $252.9 million in genomics revenue, reflecting an impressive growth rate of 117.2% year-over-year.
What did Tempus AI's CEO say about their financial position?
CEO Eric Lefkofsky emphasized that reaching positive adjusted EBITDA is a significant milestone for the company.
What changes have been made to revenue guidance for 2025?
Tempus AI has raised its revenue guidance for 2025 to $1.265 billion, indicating robust growth expectations.
How did the stock price react post-announcement?
Tempus AI's stock fell by 12.13% in after-hours trading, reflecting market volatility despite strong earnings results.